News

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics Gout Discovery Pipeline

HemoShear Therapeutics, a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and validation of two novel gout drug targets in accordance with the Horizon exclusive drug discovery agreement established in January 2019.   

“Horizon has been a great partner throughout this collaboration,” said Brian Wamhoff, PhD, chief operating officer of HemoShear. “By combining Horizon’s expertise in gout with HemoShear’s REVEAL-TxTM drug discovery platform, we are managing a research program that has generated new insights into the disease process, identified novel gout targets, and generated several first-in-class modulators of these targets.”

Under the terms of the agreement, HemoShear received an upfront payment and R&D funding, and Horizon received exclusive access to HemoShear’s proprietary disease modeling platform, to discover new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon will make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed.

Gout is a chronic, progressive inflammatory form of arthritis affecting more than nine million people in the United States that is caused by excess uric acid in the body and needs to be managed aggressively. If uric acid levels in the blood remain elevated, crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling, and joint damage. In addition to the joint damage, urate crystals can also deposit in other organs of the body, and if left unmanaged, gout can lead to significant tissue damage. Uncontrolled gout occurs when people living with gout continue to have high levels of uric acid and gout symptoms despite the use of standard oral urate-lowering therapies.

Recent News

03/13/2025

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment underscores Zynext Ventures’ commitment to supporting disruptive healthcare innovations that address significant unmet medical needs. Illexcor is developing

03/05/2025

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17. “The Catalyst works to help industry partners and academic investigators to raise follow-on

02/27/2025

Hourigan Strengthens Leadership in Advanced Manufacturing and Data Centers with Key Appointments

Hourigan is expanding its leadership team to support the firm’s growing presence in two of the region’s most technical and high-demand industries: advanced manufacturing and data centers. Hourigan has named Mark Hourigan, Jr. to lead its advanced manufacturing and logistics sector and Mark Rainey to oversee its mission-critical and data center expansion. These appointments build